Cognition Therapeutics Inc

NASDAQ:CGTX  
2.74
+0.04 (+1.48%)
Earnings Announcements

Cognition Therapeutics Provides Business Update

Published: 03/30/2022 11:12 GMT
Cognition Therapeutics Inc (CGTX) - Cognition Therapeutics Inc - Has Sufficient Cash to Fund Operations and Capital Expenditures Into Second Half of 2023.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.29

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.35

More details on our Analysts Page.